Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT00074009 Completed - Gastric Cancer Clinical Trials

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

NCT ID: NCT00072787 Completed - Gastric Cancer Clinical Trials

Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients. The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in patients with advanced gastric cancer.

NCT ID: NCT00072332 Completed - Gastric Cancer Clinical Trials

Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Start date: August 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as edotecarin and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining edotecarin with cisplatin may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining edotecarin with cisplatin in treating patients who have advanced or metastatic solid tumors.

NCT ID: NCT00062257 Completed - Gastric Cancer Clinical Trials

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Start date: June 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well irofulven works in treating patients with recurrent or metastatic gastric cancer.

NCT ID: NCT00054457 Completed - Gastric Cancer Clinical Trials

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Start date: September 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study of the effectiveness of combining docetaxel with capecitabine in treating patients who have metastatic cancer of the stomach or gastroesophageal junction.

NCT ID: NCT00054249 Completed - Gastric Cancer Clinical Trials

T900607 in Treating Patients With Gastroesophageal Junction Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.

NCT ID: NCT00052910 Completed - Gastric Cancer Clinical Trials

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

Start date: December 2002
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy after surgery may kill any remaining tumor cells following surgery. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating stomach or esophageal cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy and radiation therapy regimens in treating patients who have undergone surgery for stomach or esophageal cancer.

NCT ID: NCT00048529 Suspended - Gastric Cancer Clinical Trials

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

Start date: September 2002
Phase: Phase 2
Study type: Interventional

This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a weekly basis with an intravenous injection of the study drug.

NCT ID: NCT00040859 Completed - Gastric Cancer Clinical Trials

Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining oxaliplatin with capecitabine in treating patients who have advanced esophageal cancer or stomach cancer.

NCT ID: NCT00033657 Completed - Gastric Cancer Clinical Trials

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

Start date: August 15, 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy before and after surgery may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combining radiation therapy with two different chemotherapy regimens before and after surgery in treating patients who have esophageal cancer.